Makary, Prasad set one pivotal trial policy via NEJM article

FDA Commissioner Marty Makary and senior official Prasad stated in a New England Journal of Medicine piece that a single pivotal trial will become the new default standard for drug approvals, signaling a formal regulatory shift in evidentiary expectations. The change could shorten approval timelines and reduce development cost/risk for pipeline-stage biotechs, potentially benefiting smaller drug developers and affecting financing, M&A and valuation assumptions, while also raising questions about evidentiary robustness that investors should reprice into risk models.

Analysis

Market structure: Making a single pivotal trial the default shifts economic rents toward nimble, capital-constrained biotech sponsors and away from incumbent large-cap pharma that relied on multi-trial barriers to limit competition. Expect median time-to-market to compress by ~6–12 months for assets that previously needed two trials, improving program NPV by an estimated 10–30% and favoring small/mid-cap biotech ETFs (XBI, IBB) and cash-rich acquirers over slow-moving incumbents.

Risk assessment: Tail risks include a high-profile post-approval safety event or congressional backlash that could force reversal or tighter post-market requirements within 3–18 months; this would trigger >30% downside for over-levered small biotechs. Immediate (days) = volatility spikes in small-cap biotech; short-term (weeks–months) = re-rating and M&A speculation; long-term (quarters–years) = higher deal activity, more frequent Phase 4 burdens and payer pushback affecting realized revenues.

Trade implications: Direct plays favor long small-cap biotech exposure (XBI) and call-spread structures to control premium; pair trades can be long XBI vs short large pharma (PFE, MRK) to capture relative rerating while hedging market risk. Options: buy 3–9 month call spreads on XBI and allocate 0.5–1% to OTM puts as tail hedges; rotate overweight from regulatory-sensitive CROs to diagnostic/real-world-evidence names that monetize post-market data.

Contrarian angles: Consensus underestimates payer and liability frictions — approval ≠ reimbursement; markets may overpay for optionality (M&A) while ignoring higher eventual post-market evidence costs. Historical parallels (accelerated/conditional approvals) show initial rallies followed by volatile repricing after safety/payer shocks; position size accordingly and prefer dealable assets with clear Phase 3/real-world evidence plans.

Key Decisions for Investors

• Establish a 2–3% portfolio long in XBI (SPDR S&P Biotech ETF) via 6-month calendar: buy 1–3% notional in a 6-month ATM call / sell 20% OTM call spread to target 25–40% upside while financing premium; cut position if XBI rises >30% or if FDA issues guidance reversing single-trial policy within 90 days.
• Implement a relative-value pair: go long a basket of 6–10 small/mid-cap biotechs with Phase 2/3 readouts in next 6–12 months (equal-weight, total 2% portfolio) and short PFE 1–2% to hedge beta; rebalance on each clinical readout or M&A announcement.
• Buy downside protection: allocate 0.5–1% portfolio to 3–6 month XBI puts (10–15% OTM) to hedge a regulatory reversal or safety event that would cause >30% drawdown in small-cap biotech names.
• If FDA final guidance explicitly formalizes single pivotal trial within 60–90 days, increase biotech long exposure by additional 2% (favoring names with robust post-market evidence plans) and reduce large-cap integrated pharma exposure (PFE, MRK, JNJ) by 1–3% in favor of acquisition-target screening.